New York Blood Center, Inc.

Henrietta Nunno

Bernard Horowitz

Bolanle Williams

Shanti B Rywkin

Jay E Valinsky

Nicholas E Geacintov

The present invention concerns a process for inactivating an extracellular lipid enveloped human pathogenic virus and/or an intracellular human pathogenic virus which may be present in a blood cell composition containing &gE;1&times;10,cells/ml by contacting that composition with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of &gE;630 nm, light and oxygen and/or a quencher. In one embodiment of the invention, the process is conducted under conditions whereby a structural integrity of greater than 80% of at least one type of blood cell contained within said composition is retained. Another embodiment of the invention relates to a process for inactivating an extracellular lipid enveloped human pathogenic virus and/or an intracellular human pathogenic virus which may be present in a composition containing at least one coagulation factor while retaining at least 77% of said coagulation factor by contacting said composition with a virucidally effective amount of at least one photoreactive compound, light and a quencher. The processes of the invention can be used to prepare blood products, which, in turn, are suitable for transfusion into a recipient in need of such transfusion.

Processes for photoreactive inactivation of a virus in blood cell or coagulation factor containing compositions and use thereof for preparing compositions useful for transfusion

The present invention concerns the product produced by inactivating extracellular lipid enveloped pathogenic virus or intracellular pathogenic virus in a composition containing &gt;1.times.10.sup.9 cells/ml and said virus without incurring substantial disruption or inactivation of such cells, the inactivation process comprising contacting the composition with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of .gtoreq.630 nm, light and an oxidizer, thereby substantially to inactivate the virus with retention of cell functionality, greater than 80%. The present invention also concerns the product produced by inactivating virus in a biological composition without incurring substantial disruption or inactivation thereof, the inactivation process comprising contacting said composition with a virucidally effective amount of at least one photoreactive compound, light, and a quencher thereby to inactivate said virus while retaining functionality of said substance.

Growing community of inventors

New York, NY, United States of America

Henrietta Nunno